Univariate analysis for early death, response, and overall survival
| Variable . | n = 599 . | Early death (n = 58) . | Response CR/CRi (n = 432) . | Overall survival (months) . | |||
|---|---|---|---|---|---|---|---|
| n (%) . | P value* . | n (%) . | P value* . | Median survival . | P value† . | ||
| TDT (days) | .4134‡ | .9048‡ | .1048‡ | ||||
| 1 | 63 | 11 (17.5) | 39 (61.9) | 12.0 | |||
| 2 | 52 | 7 (13.5) | 40 (76.9) | 18.2 | |||
| 3-4 | 65 | 4 (6.2) | 50 (76.9) | 21.2 | |||
| 5-6 | 68 | 4 (5.9) | 52 (76.5) | 27.7 | |||
| 7-10 | 124 | 10 (8.1) | 85 (68.5) | 15.5 | |||
| >10 | 227 | 22 (9.7) | 166 (73.1) | 21.6 | |||
| Age (years) | .0010 | .0018 | <.0001 | ||||
| ≤60 | 358 | 23 (6.4) | 275 (76.8) | 26.1 | |||
| >60 | 241 | 35 (14.5) | 157 (65.1) | 12.1 | |||
| ECOG performance status | .0001 | .0002 | .0001 | ||||
| 0 | 173 | 7 (4.0) | 144 (83.2) | 35.7 | |||
| 1 | 196 | 14 (7.1) | 145 (74.0) | 16.6 | |||
| 2 | 65 | 9 (13.8) | 41 (63.1) | 12.3 | |||
| 3-4 | 20 | 6 (30.0) | 12 (60.0) | 6.9 | |||
| Secondary AML | .0005 | <.0001 | <.0001 | ||||
| De novo | 477 | 36 (7.5) | 366 (76.7) | 23.0 | |||
| Secondary | 122 | 22 (18.0) | 66 (54.1) | 8.6 | |||
| Extramedullary involvement [n (%)] | <.0001 | <.0001 | .0004 | ||||
| No | 357 | 19 (5.3) | 281 (78.7) | 23.7 | |||
| Yes | 151 | 16 (10.6) | 103 (68.2) | 13.5 | |||
| Leukostasis [n (%)] | <.0001 | <.0001 | <.0001 | ||||
| No | 562 | 44 (7.8) | 416 (74.0) | 19.7 | |||
| Yes | 21 | 10 (47.6) | 6 (28.6) | 1.0 | |||
| WBC (G/L) | <.0001 | .0166 | .0205 | ||||
| ≤50 | 466 | 31 (6.7) | 347 (74.5) | 20.1 | |||
| >50 | 133 | 27 (20.3) | 85 (63.9) | 14.2 | |||
| Fibrinogen [n (%)] | .1154 | .4325 | .0115 | ||||
| >4 g/L | 243 | 22 (9.1) | 175 (72.0) | 16.2 | |||
| 1.5-4 g/L | 225 | 21 (9.3) | 163 (72.4) | 21.2 | |||
| <1.5 g/L | 18 | 5 (27.8) | 10 (55.6) | 19.1 | |||
| Cytogenetics | .0527 | <.0001 | <.0001 | ||||
| Favorable | 61 | 2 (3.3) | 58 (95.1) | NR | |||
| Intermediate | 394 | 46 (11.7) | 286 (72.6) | 20.7 | |||
| Adverse | 144 | 10 (6.9) | 88 (61.1) | 9.5 | |||
| ELN | .1432 | <.0001 | <.0001 | ||||
| Favorable | 126 | 8 (6.3) | 114 (90.5) | NR | |||
| Intermediate I | 168 | 19 (11.3) | 120 (71.4) | 20.8 | |||
| Intermediate II | 161 | 21 (13.0) | 110 (68.3) | 15.4 | |||
| Adverse | 144 | 10 (6.9) | 88 (61.1) | 9.5 | |||
| Variable . | n = 599 . | Early death (n = 58) . | Response CR/CRi (n = 432) . | Overall survival (months) . | |||
|---|---|---|---|---|---|---|---|
| n (%) . | P value* . | n (%) . | P value* . | Median survival . | P value† . | ||
| TDT (days) | .4134‡ | .9048‡ | .1048‡ | ||||
| 1 | 63 | 11 (17.5) | 39 (61.9) | 12.0 | |||
| 2 | 52 | 7 (13.5) | 40 (76.9) | 18.2 | |||
| 3-4 | 65 | 4 (6.2) | 50 (76.9) | 21.2 | |||
| 5-6 | 68 | 4 (5.9) | 52 (76.5) | 27.7 | |||
| 7-10 | 124 | 10 (8.1) | 85 (68.5) | 15.5 | |||
| >10 | 227 | 22 (9.7) | 166 (73.1) | 21.6 | |||
| Age (years) | .0010 | .0018 | <.0001 | ||||
| ≤60 | 358 | 23 (6.4) | 275 (76.8) | 26.1 | |||
| >60 | 241 | 35 (14.5) | 157 (65.1) | 12.1 | |||
| ECOG performance status | .0001 | .0002 | .0001 | ||||
| 0 | 173 | 7 (4.0) | 144 (83.2) | 35.7 | |||
| 1 | 196 | 14 (7.1) | 145 (74.0) | 16.6 | |||
| 2 | 65 | 9 (13.8) | 41 (63.1) | 12.3 | |||
| 3-4 | 20 | 6 (30.0) | 12 (60.0) | 6.9 | |||
| Secondary AML | .0005 | <.0001 | <.0001 | ||||
| De novo | 477 | 36 (7.5) | 366 (76.7) | 23.0 | |||
| Secondary | 122 | 22 (18.0) | 66 (54.1) | 8.6 | |||
| Extramedullary involvement [n (%)] | <.0001 | <.0001 | .0004 | ||||
| No | 357 | 19 (5.3) | 281 (78.7) | 23.7 | |||
| Yes | 151 | 16 (10.6) | 103 (68.2) | 13.5 | |||
| Leukostasis [n (%)] | <.0001 | <.0001 | <.0001 | ||||
| No | 562 | 44 (7.8) | 416 (74.0) | 19.7 | |||
| Yes | 21 | 10 (47.6) | 6 (28.6) | 1.0 | |||
| WBC (G/L) | <.0001 | .0166 | .0205 | ||||
| ≤50 | 466 | 31 (6.7) | 347 (74.5) | 20.1 | |||
| >50 | 133 | 27 (20.3) | 85 (63.9) | 14.2 | |||
| Fibrinogen [n (%)] | .1154 | .4325 | .0115 | ||||
| >4 g/L | 243 | 22 (9.1) | 175 (72.0) | 16.2 | |||
| 1.5-4 g/L | 225 | 21 (9.3) | 163 (72.4) | 21.2 | |||
| <1.5 g/L | 18 | 5 (27.8) | 10 (55.6) | 19.1 | |||
| Cytogenetics | .0527 | <.0001 | <.0001 | ||||
| Favorable | 61 | 2 (3.3) | 58 (95.1) | NR | |||
| Intermediate | 394 | 46 (11.7) | 286 (72.6) | 20.7 | |||
| Adverse | 144 | 10 (6.9) | 88 (61.1) | 9.5 | |||
| ELN | .1432 | <.0001 | <.0001 | ||||
| Favorable | 126 | 8 (6.3) | 114 (90.5) | NR | |||
| Intermediate I | 168 | 19 (11.3) | 120 (71.4) | 20.8 | |||
| Intermediate II | 161 | 21 (13.0) | 110 (68.3) | 15.4 | |||
| Adverse | 144 | 10 (6.9) | 88 (61.1) | 9.5 | |||